The Nationwide Inpatient Sample aggregated data from approximately 20% of US hospital admissions from 1993 to 2011. Prior literature found that pneumonia admissions decreased following the introduction of the pneumococcal vaccine in 2000. 1 The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), codes provide information regarding pneumonia pathogens, but no studies, to our knowledge, have used these codes to analyze longitudinal trends in the pathogens documented during hospitalizations for pneumonia.
Methods | We selected patients 18 years or older admitted for pneumonia based on a principal diagnosis of pneumonia (ICD-9-CM codes 480. 0-480.3, 480.8, 480.9, 481, 482.0-482.9, 483.0-483.8, 485, 486, and 487) . Consistent with recent literature, 2 we also selected hospitalizations with pneumonia as a secondary diagnosis if the principal diagnosis was sepsis 038.9, 785.52, 995.91, and 995.92) or respiratory failure 518.82, 518.84, and 799.1) . For each pathogen, we used a linear regression model with year of hospitalization as the explanatory variable and the percentage of cases coded with that pathogen as the dependent variable. We obtained annual population estimates from the US Census Bureau. 3
Results | From January 1, 1993, to December 31, 2011, hospitalizations for pneumonia increased from 910 676 to 1 378 551 (350.4 to 442.4 per 100 000 US population; P < .001) (Table and Figure) . The proportion of admissions with no reported pathogen increased from 65.9% to 83.9% (P < .001). Admissions with the nonpneumonia principal diagnoses were more likely to have pathogens documented (odds ratio, 1.28; 95% CI, 1.25-1.30; P < .001). From 1993 to 2011, there were declines in the coding of streptococcal species (from 7.1% to 2.3%; P < .001), Pseudomonas (from 3.9% to 2.3%; P < .001), and Haemophilus influenzae (from 3.6% to 0.4%; P < .001); however, the coding of Staphylococcus aureus increased (from 3.6% to 3.9%; P = .004). Unadjusted inpatient mortality did not change significantly (from 8.7% to 7.8%; P = .40). Cases coded with S aureus had the highest mortality (12.0%).
Discussion | To our knowledge, this is the first analysis of trends in the microbiologic pathogens in patients hospitalized for pneumonia based on nationally representative data spanning nearly 2 decades.
Streptococcus pneumoniae has been reported to be the most common cause of community-acquired pneumonia. 4 Declines in cases of adult pneumonia due to S pneumoniae may be related to more frequent and effective vaccination as well as to herd immunity from increased pediatric vaccination after 2000. 1 In addition to prevention, vaccination reduces the risk of invasive pneumococcal disease and bacteremia. We hypothesize that this reduced risk may have resulted in less-frequent coding because more thorough diagnostic evaluations accompany a higher severity of disease. 5 We observed a reduction in Streptococcus, despite the addition of urine antigen testing. 6 Furthermore, quality improvement initiatives to reduce the time from presentation to antibiotic administration may also have reduced the yield of traditional culture-based diagnostics. We cannot know with certainty how the contributions of vaccination and changes in diagnostic tests affected the trends that we describe. However, we believe that our findings suggest important changes in pneumonia pathogens.
Streptococcus pneumoniae was the most frequent pathogen in 1993 and S aureus was the most frequent in 2011, most of which was methicillin-resistant S aureus (MRSA). Because we included hospitalizations with certain alternative principal diagnoses, it is likely that our case definition included some patients with health care-associated pneumonia, which may have increased our identification of MRSA. Despite the trends observed, the low incidence of S aureus (<4%) suggests that MRSA coverage is not routinely indicated for patients with community-acquired pneumonia. 7 We have described changes in pneumonia pathogens from hospital admissions during 2 decades. We believe that these changes should be considered for public health monitoring and care for pneumonia, which is the leading cause of infectious death in the United States. 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2010 2011 Admissions for Pneumonia, %
Year
Haemophilus influenzae
Staphylococcal species
Pseudomonas
Streptococcal species
Streptococcal species, especially
Streptococcus pneumoniae, were the most frequently coded pathogens in 1993. There were decreases in the documentation of streptococcal species, Haemophilus influenzae, and Pseudomonas, whereas documentation of Staphylococcus aureus increased modestly.
Contemporary Nationwide Patterns of Self-reported Prostate-Specific Antigen Screening
Routine screening for prostate cancer using prostate-specific antigen (PSA) is a widely contested practice, and recommendations have recently changed dramatically. In October 2011, the US Preventative Services Task Force recommended against screening in any age group, 1 yet current nationwide patterns of PSA screening are largely unknown. We sought to elucidate contemporary PSA screening prevalence with a focus on heterogeneity among states and across age groups. We examine data from the 2012 Behavioral Risk Factor Surveillance System (BRFSS).
Methods | The BRFSS is the world's largest continuously conducted health survey, a joint initiative of the Centers for Disease Control and Prevention and US states. Male respondents 50 years or older without a history of prostate cancer or prostate problem who reported PSA testing within the 12 months preceding the 2012 BRFSS survey were considered to have undergone screening. The 2012 survey was conducted between January 2, 2012, and February 12, 2013. Complex-samples logistic regression analysis incorporating age, race and/or eth-nicity, education, income, residence location, insurance status, access to regular health care, and marital status was used to estimate an individual's predicted probability of undergoing PSA screening. Individual probabilities were then normalized to the 2012 BRFSS screened population to derive statespecific estimates of screening prevalence.
Results | In 2012, 114 544 unique responses from men 50 years or older were captured by the BRFSS, a weighted estimate of 46.24 million men, of whom 17.16 million (37.1%) reported undergoing PSA screening. Access to regular health care was most strongly associated with higher rates of screening (odds ratio [OR], 3.00 [95% CI, 2.69-3.34]). Additional predictors included income greater than $75 000 (OR, 1.91 [95% CI, 1.67-2.20]), college education (OR, 1.90 [95% CI, 1.70-2.12]), health insurance (OR, 1.83 [95% CI, 1.60-2.08]), and age 70 to 74 years (OR, 2.53 [95% CI, ) (see eTable in the Supplement). After adjustment for covariates, the estimated prevalence of self-reported PSA screening was highest in Hawaii (59.4%) and lowest in New Hampshire (24.5%) ( Figure 1) . The prevalence of PSA screening was highest in older men aged 65 to 69 years (48.4%) and 70 to 74 years (48.5%). Men aged 50 to 54 years were the least likely to report PSA screening (25.0%) ( Figure 2) .
Discussion | Whereas changes in sampling methodology preclude direct comparison with prior years of the BRFSS, our data show that the effect of previous guidelines recommending against the routine screening of elderly men has been minimal at best. 2 Prior work exploring PSA screening trends following earlier US Preventative Services Task Force recommendations against screening in men older than 75 years demonstrated no significant reduction, and yet men aged 75 to 79 years remain the third most likely age group to undergo screening in the year preceding the survey (weighted estimate, 45.7% [95% CI, 43.6%-47.9%]). 3 Equally remarkable is the low rate of PSA screening (weighted estimate, 25.0% [95% CI, 23.8%-26.2%]) among men between 50 and 54 years old, for whom screening has previously been recommended by several professional organizations. These findings likely reflect both the considerable disagreement among experts and the conflicting recommendations. Taken together, these results suggest that national guidelines have had limited effect on clinical practice among health care providers.
The degree of heterogeneity in state-by-state PSA screening prevalence is another concerning and surprising study finding. Evidence from the colorectal and breast cancer screening literature suggests that state-by-state and regional variability is expected but not to such a pronounced extent. For example, regional variability in colorectal screening rates is only 7.5%. 4 It is alarming that the prevalence of PSA screening can double from one state to the next. Whereas the causes of this heterogeneity may mirror those in mammography, including variability in the availability of large university hospitals, geographic density of providers, levels of insurance coverage, and income, 5 the effect of physician preferences on the odds of screening is far more pronounced for PSA, relative to other screening tests. 6 Limitations of our study include recall and nonresponse bias. Inaccuracies in self-reported PSA screening have been
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